Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Vector Pharma","sponsor":"R-Pharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vector Pharma FZCO signs Exclusive License and Distribution Rights to IXEMPRA in the Middle East","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"U.A.E","productType":"Small molecule","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Vector Pharma","sponsor":"Ascendis Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vector Pharma FZCO Announce Exclusive Distribution Agreement with Ascendis Pharma A\/S for Skytrofa (lonapegsomatropin) and Yorvipath (palopegteriparatide) in Gulf Cooperation Council Countries","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"U.A.E","productType":"Large molecule","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"Vector Pharma","sponsor":"Oncopeptides","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"U.A.E","productType":"Peptide","productStatus":"Approved","date":"March 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Vector Pharma","sponsor":"Oncopeptides","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oncopeptides, Vector partner to distribute Oncopeptides\u2019 Pepaxti in MENA region to treat multiple myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"U.A.E","productType":"Peptide","productStatus":"Approved","date":"March 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Vector Pharma

    Menu

    Vector Pharma

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Vector Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.A.E
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Oncopeptides, Vector partner to distribute Oncopeptides’ Pepaxti in MENA region to treat multiple myeloma

              Details:

              Under the collaboration, Vector will distribute Pepaxti (melphalan flufenamide), indicated in combination with dexamethasone, to patients in the MENA region for the treatment of patients with multiple myeloma.

              Lead Product(s): Melphalan Flufenamide,Dexamethasone

              Therapeutic Area: Oncology Product Name: Pepaxti

              Highest Development Status: Approved Product Type: Peptide

              Recipient: Oncopeptides

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration March 30, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Vector Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.A.E
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Oncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa

              Details:

              Under the agreement, Vector will distribute Pepaxti (melphalan flufenamide), indicated in combination with dexamethasone, in the MENA region for the treatment of patients with multiple myeloma.

              Lead Product(s): Melphalan Flufenamide,Dexamethasone

              Therapeutic Area: Oncology Product Name: Pepaxti

              Highest Development Status: Approved Product Type: Peptide

              Recipient: Oncopeptides

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration March 27, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Vector Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.A.E
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Vector Pharma FZCO Announce Exclusive Distribution Agreement with Ascendis Pharma A/S for Skytrofa (lonapegsomatropin) and Yorvipath (palopegteriparatide) in Gulf Cooperati...

              Details:

              Vector will employ its sales and marketing expertise to distribute both Skytrofa (lonapegsomatropin-tcgd) and Yorvipath in the GCC countries for pediatric growth hormone deficiency in the case of Skytrofa, and adult hypoparathyroidism in the case of Yorvipath.

              Lead Product(s): Lonapegsomatropin

              Therapeutic Area: Endocrinology Product Name: Skytrofa

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Ascendis Pharma

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement January 08, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Vector Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.A.E
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Vector Pharma FZCO signs Exclusive License and Distribution Rights to IXEMPRA in the Middle East

              Details:

              Under the agreement, R-PHARM US has appointed Vector Pharma as exclusive distributor to import, use, market, sell and distribute Ixempra (ixabepilone) in the Middle East & North African territories.

              Lead Product(s): Ixabepilone,Capecitabine

              Therapeutic Area: Oncology Product Name: Ixempra

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: R-Pharm

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement December 22, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY